Cargando…

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors

Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5’-nucleotidase (CD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schäkel, Laura, Schmies, Constanze C., Idris, Riham M., Luo, Xihuan, Lee, Sang-Yong, Lopez, Vittoria, Mirza, Salahuddin, Vu, The Hung, Pelletier, Julie, Sévigny, Jean, Namasivayam, Vigneshwaran, Müller, Christa E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508162/ https://www.ncbi.nlm.nih.gov/pubmed/33013365 http://dx.doi.org/10.3389/fphar.2020.01294

Ejemplares similares

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
por: Schäkel, Laura, et al.
Publicado: (2022)

Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39
por: Lopez, Vittoria, et al.
Publicado: (2021)

Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
por: Goueli, Said A., et al.
Publicado: (2019)

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023)

The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation
por: Roberts, Veena, et al.
Publicado: (2014)

Resident Cardiac Immune Cells and Expression of the Ectonucleotidase Enzymes CD39 and CD73 after Ischemic Injury
por: Bönner, Florian, et al.
Publicado: (2012)

Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer
por: Zhulai, G. A., et al.
Publicado: (2023)

NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow
por: Favre, Julie, et al.
Publicado: (2023)

HPV-16 Infection Is Associated with a High Content of CD39 and CD73 Ectonucleotidases in Cervical Samples from Patients with CIN-1
por: de Lourdes Mora-García, María, et al.
Publicado: (2019)

Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function
por: Nagate, Yasuhiro, et al.
Publicado: (2020)

T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1
por: Trad, Malika, et al.
Publicado: (2015)

Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
por: Crooke, Almudena, et al.
Publicado: (2017)

CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)

CD39/CD73/A2AR pathway and cancer immunotherapy
por: Xia, Chenglai, et al.
Publicado: (2023)

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023)

The Inhibition of CD39 and CD73 Cell Surface Ectonucleotidases by Small Molecular Inhibitors Enhances the Mobilization of Bone Marrow Residing Stem Cells by Decreasing the Extracellular Level of Adenosine
por: Adamiak, Mateusz, et al.
Publicado: (2019)

The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis
por: Peng, Zhen‐Wei, et al.
Publicado: (2017)

High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors
por: Aliagas, Elisabet, et al.
Publicado: (2014)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

CD73 Ectonucleotidase Restrains CD8+ T Cell Metabolic Fitness and Anti-tumoral Activity
por: Briceño, Pedro, et al.
Publicado: (2021)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK
por: Rajak, Jovana, et al.
Publicado: (2023)

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
por: Deaglio, Silvia, et al.
Publicado: (2007)

The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain
por: Matyash, Marina, et al.
Publicado: (2017)

Helios, CD73 and CD39 Induction in Regulatory T Cells Exposed to Adipose Derived Mesenchymal Stem Cells
por: Fakhimi, Maryam, et al.
Publicado: (2020)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease
por: Kudryavtsev, Igor, et al.
Publicado: (2019)

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
por: Horenstein, Alberto L, et al.
Publicado: (2013)

CD39 Regulation and Functions in T Cells
por: Timperi, Eleonora, et al.
Publicado: (2021)

Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4(+) CD25(high)Foxp3(+) regulatory T‐cells in psoriasis
por: Han, Ling, et al.
Publicado: (2017)

Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over
por: Kling, Lovis, et al.
Publicado: (2017)

Comparison of the expression of cluster of differentiation (CD)39 and CD73 between propofol- and sevoflurane-based anaesthesia during open heart surgery
por: Oh, Chung-Sik, et al.
Publicado: (2018)

Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression
por: Muñóz-Godínez, Ricardo, et al.
Publicado: (2020)

Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B
por: Zhou, Shuang-Nan, et al.
Publicado: (2020)

The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition
por: Bauer, Arthur, et al.
Publicado: (2022)

CD39 Expression Identifies Terminally Exhausted CD8(+) T Cells
por: Gupta, Prakash K., et al.
Publicado: (2015)

Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer
por: Tøndell, Anders, et al.
Publicado: (2019)

CD39 and control of cellular immune responses
por: Dwyer, Karen M., et al.
Publicado: (2007)

The Role of Cluster of Differentiation 39 (CD39) and Purinergic Signaling Pathway in Viral Infections
por: Elsaghir, Alaa, et al.
Publicado: (2023)

Inhibitory Molecules PD-1, CD73 and CD39 Are Expressed by CD8(+) T Cells in a Tissue-Dependent Manner and Can Inhibit T Cell Responses to Stimulation
por: Smith, Corinne J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4iu3pjtmk1rmp8do8bfgoq11hh